CINECA IRIS Institutional Research Information System

LEONE, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.335
AS - Asia 4.131
EU - Europa 3.768
SA - Sud America 280
OC - Oceania 88
AF - Africa 48
Continente sconosciuto - Info sul continente non disponibili 12
Totale 14.662
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.159
CN - Cina 2.097
IT - Italia 945
SG - Singapore 727
DE - Germania 532
JP - Giappone 397
GB - Regno Unito 358
FR - Francia 353
IE - Irlanda 275
ES - Italia 245
BR - Brasile 233
SE - Svezia 213
IN - India 171
FI - Finlandia 139
CA - Canada 132
KR - Corea 132
UA - Ucraina 116
HK - Hong Kong 104
VN - Vietnam 94
TR - Turchia 88
TW - Taiwan 85
PL - Polonia 83
AU - Australia 71
CH - Svizzera 71
NL - Olanda 64
BE - Belgio 60
RU - Federazione Russa 55
GR - Grecia 51
ID - Indonesia 46
TH - Thailandia 46
AT - Austria 42
MX - Messico 35
SA - Arabia Saudita 31
CZ - Repubblica Ceca 28
RO - Romania 26
IR - Iran 23
PT - Portogallo 23
DK - Danimarca 20
AR - Argentina 18
EG - Egitto 17
NZ - Nuova Zelanda 17
IL - Israele 16
MY - Malesia 16
HU - Ungheria 13
CL - Cile 12
PK - Pakistan 10
EU - Europa 9
HR - Croazia 8
ZA - Sudafrica 8
SI - Slovenia 7
BG - Bulgaria 6
CO - Colombia 6
KE - Kenya 6
LB - Libano 6
AM - Armenia 5
JO - Giordania 5
OM - Oman 5
PE - Perù 5
PH - Filippine 5
BA - Bosnia-Erzegovina 4
BD - Bangladesh 4
EE - Estonia 4
LU - Lussemburgo 4
NO - Norvegia 4
AP - ???statistics.table.value.countryCode.AP??? 3
BY - Bielorussia 3
DZ - Algeria 3
GE - Georgia 3
IS - Islanda 3
MA - Marocco 3
MK - Macedonia 3
SK - Slovacchia (Repubblica Slovacca) 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BN - Brunei Darussalam 2
DO - Repubblica Dominicana 2
GH - Ghana 2
IM - Isola di Man 2
LT - Lituania 2
NP - Nepal 2
PA - Panama 2
PR - Porto Rico 2
QA - Qatar 2
SN - Senegal 2
TG - Togo 2
TN - Tunisia 2
UY - Uruguay 2
UZ - Uzbekistan 2
AL - Albania 1
BB - Barbados 1
BO - Bolivia 1
BT - Bhutan 1
CY - Cipro 1
EC - Ecuador 1
ET - Etiopia 1
IQ - Iraq 1
LV - Lettonia 1
MU - Mauritius 1
NG - Nigeria 1
NI - Nicaragua 1
Totale 14.658
Salva come PNG Salva come JPEG
Città #
Beijing 547
Chandler 473
Fairfield 384
Singapore 371
Houston 340
Santa Clara 314
Shanghai 294
Dublin 272
Ashburn 238
Woodbridge 208
Seattle 203
Wilmington 203
Ann Arbor 193
Redwood City 164
Torino 150
Cambridge 147
Guangzhou 131
Dearborn 125
Villeurbanne 125
Nyköping 113
Tokyo 112
Jacksonville 107
Pisa 102
Princeton 94
Columbus 92
Nanjing 90
Milan 87
Medford 84
New York 78
Warsaw 70
Munich 60
Zhengzhou 57
Dong Ket 55
Wuhan 55
Boston 54
Chengdu 51
Hangzhou 49
Taipei 48
Paris 44
London 43
Duncan 41
San Diego 41
Jakarta 40
Rome 39
Turin 39
Hefei 38
Hong Kong 38
Jinan 38
Chicago 37
Istanbul 36
Madrid 36
Los Angeles 35
The Dalles 35
Toronto 35
Barcelona 31
Brussels 30
São Paulo 29
Silver Spring 27
Boardman 26
Norwalk 26
Seoul 25
Shenyang 24
Tianjin 24
Ottawa 23
Mumbai 21
Nuremberg 21
Phoenix 21
Berlin 20
Fremont 20
Salt Lake City 20
Aioicho 19
Amsterdam 19
Chongqing 19
Shenzhen 19
Helsinki 18
Philadelphia 18
Sydney 18
Changsha 17
Montreal 17
San Francisco 17
Dallas 16
Düsseldorf 16
Atlanta 15
Hebei 15
Manchester 15
Nanchang 15
Riyadh 15
Athens 13
Bangkok 13
Melbourne 13
Nutley 13
Vienna 13
Bari 12
Newbury Park 12
Pune 12
Rochester 12
San Mateo 12
Vancouver 12
Verona 12
Washington 12
Totale 7.792
Salva come PNG Salva come JPEG
Nome #
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial 5.560
Emerging molecular target antagonists for the treatment of biliary tract cancer 687
A phase I dose-escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. 462
Potentially resectable metastatic colorectal cancer: An individualized approach to conversion therapy. 291
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study) 262
Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18 F-FDG PET and MRI radiomics features 244
Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy 243
Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor 204
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity 171
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 169
Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma 168
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. 166
The Role of Lung Metastasis Resection in Improving Outcome of Colorectal Cancer Patients: Results from a Large Retrospective Study. 160
Tracking the 2015 gastrointestinal cancers symposium: Bridging cancer biology to clinical gastrointestinal oncology 158
Fluoropyrimidine-induced cardiotoxicity 151
Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: A case report 150
Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR 148
Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine 140
Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. 139
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma 139
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: A multicenter survey and pooled analysis with published data 134
HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives 133
Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients 131
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas 126
Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line 124
The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005 122
PHASE II TRIAL OF PANITUMUMAB IN COMBINATION WITH OXALIPLATIN AND CAPECITABINE CHEMOTHERAPY AS 1ST LINE THERAPY IN PATIENTS WITH COLORECTAL CANCER AND ADVANCED LIVER METASTASES: THE METAPAN STUDY 117
Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? 114
Bone metastases in biliary cancers: A multicenter retrospective survey 112
Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives 111
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. 109
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 108
Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab 106
Antitumor activity of Src inhibitor Saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. 104
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases: The MetaPan study. 100
Rationale for the use of metronomic chemotherapy in gastrointestinal cancer 98
High prevalence of hepatitis C virus (HCV) genotype 2 in Italian patients with chronic liver disease. 95
Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR. 94
Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient 91
Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction. 90
[Diagnosis of neoplastic ascites: combined use of albumin gradient between serum and ascites and cholesterol in ascitic fluid] 88
GAS6, the ligand of Axl and Rse receptors, is expressed in hematopoietic tissue but lacks mitogenic activity. 83
Biliary tract carcinomas: From chemotherapy to targeted therapy. 82
Epidemiological and virological analysis of couples infected with hepatitis C virus. 81
LONG-TERM SURVIVAL OF PATIENTS WITH RESECTION OF PULMONARY METASTASES FROM COLORECTAL NEOPLASMS AS COMPARED TO NOT RESECTED ONES. A RETROSPECTIVE STUDY ON PATIENTS FOLLOWED FROM THE TIME OF FIRST RECURRENCE 81
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 81
Diagnostic paracentesis. A two-step approach. 80
Tumor cell purging by ex vivo expansion of hemopoietic stem cells from breast cancer patients combined with targeting ErbB receptors 78
Capecitabine with/without mitomycin C: Results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma 77
Assessment of a HER2 scoring system for colorectal cancer: Results from a validation study 77
A novel multidrug‐resistant cell line from an italian intrahepatic cholangiocarcinoma patient 77
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 74
Adjuvant chemotherapy and follow-up 73
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 72
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study 72
Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy 71
Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients 70
Linifanib: Current status and future potential in cancer therapy 69
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 69
Evaluation of iron status in patients with chronic hepatitis C. 67
“Shades of Gray” in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer 67
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 65
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 63
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center 62
Outcome of metastatic colorectal cancer: analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach 62
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 60
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy 60
Targeted agents: how can we improve the outcome in biliary tract cancer? 59
Fluoropyrimidine‑induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT) 59
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 56
Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience 52
Phlebotomy reduces serum procollagen III peptide levels in patients with chronic hepatitis C. 52
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 52
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 51
Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. 50
Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy 49
Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. 48
Hepatitis C virus (HCV) hypervariable region 1 complexity does not correlate with severity of liver disease, HCV type, viral load or duration of infection. 46
Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. 45
Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma 43
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 42
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 41
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 41
Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma 40
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 39
Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience 39
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 39
Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: A single institutional experience. 38
Abstract 2848: Radiographic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer 35
Doxycycline Restores Gemcitabine Sensitivity in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma 14
Viral Hepatitis in Western Patients with Advanced Intrahepatic Cholangiocarcinoma: Retrospective Assessment of Prevalence, Prognostic and Predictive Significance 13
Totale 15.035
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.304
article - articoli 0
book - libri 0
conference - conferenze 721
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.025
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020114 0 0 0 0 0 0 0 0 0 0 0 114
2020/20211.620 111 126 146 136 138 101 137 99 166 138 131 191
2021/20221.652 130 138 96 108 130 95 133 145 90 92 286 209
2022/20231.882 191 173 71 171 155 341 146 125 197 90 137 85
2023/20241.412 143 176 109 113 115 145 101 117 28 91 132 142
2024/20252.515 73 188 163 224 473 205 102 151 307 185 214 230
Totale 15.035